PRLD News and Press, Prelude Therapeutics Incorporated

2026-06-10 14:42:16 ET Prelude Therapeutics Incorporated (PRLD) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 10, 2026 11:20 AM EDT... Read the full article on Seeking Alpha For further details see: Prelude Therapeutics Incorporated (PRLD) Presents at Gold...

2026-05-12 07:34:14 ET More on Prelude Therapeutics Prelude Therapeutics prices $90M equity offering Seeking Alpha’s Quant Rating on Prelude Therapeutics Historical earnings data for Prelude Therapeutics Financial information for Prelude Therapeutics ...

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF) The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiat...

2026-04-20 06:38:52 ET More on Prelude Therapeutics Prelude climbs as FDA clears study for Incyte-partnered cancer candidate Seeking Alpha’s Quant Rating on Prelude Therapeutics Historical earnings data for Prelude Therapeutics Financial information fo...

WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the pricing of its underwritten offering of 18,018,014 shares of its voting ...

Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX Models of HR+/HER2- Breast Cancer  Prelude Remains on Track to File Investigational New Drug (IND) Application by mid-2026 and to initiate clinic...

WILMINGTON, Del., April 15, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude Therapeutics” or the “Company”), a clinical-stage precision oncology company, today announced that Dr. Charles Morris will join the Company as Chief Medical ...

WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company’s oral KAT6A selective degrader (PRT13722) has been accepted for presentation at the Ameri...

2026-03-10 07:30:52 ET More on Prelude Therapeutics Prelude climbs as FDA clears study for Incyte-partnered cancer candidate Seeking Alpha’s Quant Rating on Prelude Therapeutics Historical earnings data for Prelude Therapeutics Financial information fo...

Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026 Preclinical development an...